Scarica l'app Stockscreener
14.34
6.62%
0.89
Dopo l'orario di chiusura:
14.20
-0.14
-0.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Arcturus (ARCT) Results Review: EPS Comes in Above Forecast in the Latest Reading; Stock Move: The Market Price Advances 19.85% on the DayGeographic Revenue Trends - Vinanet
ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows - StocksToTrade
ARCT Stock Jumps As Canaccord Backs Vaccine Reset - timothysykes.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough - Sahm
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Liquidity Mapping Around (ARCT) Price Events - Stock Traders Daily
We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Moomoo
Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (ARCT) Surges 5.92% to $8.05, Approaches Key Resistance at $8.45Low Volatility Picks - vinanet.vn
HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - MarketBeat
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - MarketBeat
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $20 - Moomoo
Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside - TradingView
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - BioSpace
ARCT Looks 57.9% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view By Investing.com - Investing.com South Africa
Arcturus Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view - Investing.com
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary - TradingView
Q2 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus
Arcturus Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Arcturus Therapeutics reports Q2 2026: $3.0M revenue, $23.8M net loss, $191.5M cash - TradingView
Arcturus Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Why (ARCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% Downside - Yahoo Finance
Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a shareEarnings Preview - TradingView
ARCT Q1 2026 Earnings: Loss Narrower Than Expected as Shares Dip 2.7%Earnings Quality Score - Vinanet
Arcturus Therapeutics (NASDAQ:ARCT) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Arcturus Therapeutics (ARCT) to Announce Quarterly Earnings on Thursday - MarketBeat
Arcturus Therapeutics (ARCT) Slips 0.61% as Stock Hovers Near Key Support LevelMomentum ETF - vinanet.vn
Arcturus Therapeutics Q2 Results: Financials and update due Aug 6 - scanx.trade
Arcturus Therapeutics Holdings Inc - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Cash Flow - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260 - TradingKey
Arcturus Therapeutics Holdings Inc. Revenue Breakdown – NASDAQ:ARCT - TradingView
Arcturus Therapeutics (ARCT) Falls 2.36% to $5.79 as Stock Approaches Critical SupportETF Premium Discount - dars.gov.et
Arcturus Therapeutics Holdings Inc (ARCT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Amova Asset Management Americas Inc. Grows Stock Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - BioSpace
Arcturus: Now That It's Come This Low, It's Time To Buy And Hold (NASDAQ:ARCT) - Seeking Alpha
Arcturus Therapeutics (ARCT) Q1 2026 Earnings: Loss Narrows as Pipeline Progress Offsets Revenue Absence - Vinanet
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Arcturus Therapeutics (ARCT) Slips 3.7% as Shares Approach Key SupportIron Condor Alert - vinanet.vn
Understanding Momentum Shifts in (ARCT) - Stock Traders Daily
Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis - Kavout | AI
ARCT Should I Buy - Intellectia AI
Arcturus Therapeutics (ARCT) Q1 2025 earnings summary - Quartr
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):